1. Home
  2. GKOS vs BEPC Comparison

GKOS vs BEPC Comparison

Compare GKOS & BEPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • BEPC
  • Stock Information
  • Founded
  • GKOS 1998
  • BEPC 2019
  • Country
  • GKOS United States
  • BEPC United States
  • Employees
  • GKOS N/A
  • BEPC N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • BEPC Electric Utilities: Central
  • Sector
  • GKOS Health Care
  • BEPC Utilities
  • Exchange
  • GKOS Nasdaq
  • BEPC Nasdaq
  • Market Cap
  • GKOS 5.8B
  • BEPC 6.1B
  • IPO Year
  • GKOS 2015
  • BEPC N/A
  • Fundamental
  • Price
  • GKOS $94.32
  • BEPC $36.43
  • Analyst Decision
  • GKOS Strong Buy
  • BEPC Buy
  • Analyst Count
  • GKOS 12
  • BEPC 3
  • Target Price
  • GKOS $134.67
  • BEPC $33.67
  • AVG Volume (30 Days)
  • GKOS 869.3K
  • BEPC 912.4K
  • Earning Date
  • GKOS 07-30-2025
  • BEPC 08-01-2025
  • Dividend Yield
  • GKOS N/A
  • BEPC 4.09%
  • EPS Growth
  • GKOS N/A
  • BEPC N/A
  • EPS
  • GKOS N/A
  • BEPC N/A
  • Revenue
  • GKOS $404,523,000.00
  • BEPC $3,923,000,000.00
  • Revenue This Year
  • GKOS $27.88
  • BEPC $44.37
  • Revenue Next Year
  • GKOS $27.60
  • BEPC $7.44
  • P/E Ratio
  • GKOS N/A
  • BEPC N/A
  • Revenue Growth
  • GKOS 23.92
  • BEPC N/A
  • 52 Week Low
  • GKOS $77.10
  • BEPC $23.73
  • 52 Week High
  • GKOS $163.71
  • BEPC $36.96
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 37.61
  • BEPC 67.99
  • Support Level
  • GKOS $92.42
  • BEPC $35.86
  • Resistance Level
  • GKOS $98.21
  • BEPC $36.96
  • Average True Range (ATR)
  • GKOS 2.85
  • BEPC 0.80
  • MACD
  • GKOS -1.10
  • BEPC 0.14
  • Stochastic Oscillator
  • GKOS 13.19
  • BEPC 87.72

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About BEPC Brookfield Renewable Corporation

Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.

Share on Social Networks: